Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 67, Issue 1, pp 49–56 | Cite as

DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity

  • Chen Guang Yang
  • Joseph Ciccolini
  • Aurore Blesius
  • Laetitia Dahan
  • Danielle Bagarry-Liegey
  • Caroline Brunet
  • Arthur Varoquaux
  • Nicolas Frances
  • Hafedh Marouani
  • Antoine Giovanni
  • Rose-Marie Ferri-Dessens
  • Mohamed Chefrour
  • Roger Favre
  • Florence Duffaud
  • Jean-François Seitz
  • Michel Zanaret
  • Bruno Lacarelle
  • Cédric MercierEmail author
Original Article

Abstract

Background

Fluoropyrimidine drugs are widely used in head and neck cancer (HNC). DPD deficiency is a pharmacogenetics syndrome associated with severe/lethal toxicities upon 5-FU or capecitabine intake. We have developed a simple, rapid, and inexpensive functional testing for DPD activity, as a means to identify deficient patients and to anticipate subsequent 5-FU-related toxicities. We present here the impact of fluoropyrimidine dose tailoring based on DPD functional screening in a prospective, open, non-controlled study, both in term of reduction in severe toxicities and of treatment efficacy.

Methods

About 65 patients with HNC (59 ± 9 years, 52M/13F, Prospective Group) were entered into the study. Screening for DPD deficiency was performed prior to the beginning of the chemotherapy or radiochemotherapy. DPD status was evaluated by monitoring U/UH2 ratio levels in plasma as a surrogate marker for enzymatic functionality. 5-FU doses were reduced according to the extent of the detected DPD impairment, and adjusted on the basis of age, general condition, and other clinical/paraclinical covariates, if required. Treatment-related toxicities and subsequent impact on treatment delay were carefully monitored next for comparison with a retrospective, Reference subset of 74 other patients with HNC (mean age: 59 ± 10, 58M/16F, Reference Group), previously treated in the same institute with similar schedule but using standard 5-FU dosage.

Results

Thirty-one out of 65 patients (48%) were identified as mildly (28%) to markedly (20%) DPD deficient. Subsequently, dose reductions ranging from 10 to 100% with 5-FU were applied in those patients. In this group, six patients (9%) experienced severe toxicities, none of them being life threatening, and no toxic death was encountered. In comparison, 16 out of 74 patients (22%) of the Reference Group displayed severe side effects after standard 5-FU administration, 13% being life-threatening toxicities (e.g., G4 neutropenia + sepsis). Moreover, one toxic death was observed in this Reference Group. No postponement or cancelation of forthcoming chemoradiotherapy courses occurred in the Prospective Group, whereas treatment had to be disrupted in six patients (8%) from the Reference Group. No difference in first-line therapy efficacy was evidenced between the two subsets (78 vs. 79% response, P = 0.790).

Conclusions

Although non-randomized, this study strongly suggests that prospective determination of DPD status has an immediate clinical benefit by reducing the drug-induced toxicities incidence in patients treated with 5-FU, allowing an optimal administration of several courses in a row, while maintaining efficacy. Our preliminary results thus advocate for systematic DPD screening in patients eligible for treatment with fluoropyrimidine drugs in HNC.

Keywords

5-Fluorouracil DPD Toxicity Dose tailoring Efficacy Head and neck cancer 

Notes

Acknowledgments

Dr. Chen Guang Yang had a generous grant from the Ambassade de France en Chine (French embassy in China). This work was supported by the Association pour la Recherche contre le Cancer (Grant #1094), by the Groupe des Entreprises Finançant la Lutte contre le Cancer (GEFLUC-Marseille Provence) and by Roche Oncologie France.

References

  1. 1.
    Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN (1994) Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12:2648–2653PubMedGoogle Scholar
  2. 2.
    Budach W, Hehr T, Budach V, Belka C, Dietz K (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28CrossRefPubMedGoogle Scholar
  3. 3.
    Choong N, Vokes E (2008) Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin 58:32–53CrossRefPubMedGoogle Scholar
  4. 4.
    Chua D, Wei WI, Sham JS, Au GK (2008) Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer. Jpn J Clin Oncol 38:244–249CrossRefPubMedGoogle Scholar
  5. 5.
    Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer JC, Richard K, Dales JP, Durand A, Milano G, Seitz JF, Lacarelle B (2006) Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine dehydrogenase deficiency. Cancer Chemother Pharmacol 58:272–275CrossRefPubMedGoogle Scholar
  6. 6.
    Ciccolini J, Mercier C, Evrard A, Dahan L, Boyer JC, Duffaud F, Richard K, Blanquicett C, Milano G, Blesius A, Durand A, Seitz JF, Favre R, Lacarelle B (2006) A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 28:678–685CrossRefPubMedGoogle Scholar
  7. 7.
    Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T, Merlin JL, Riviere A, Perrocheau G, Etienne MC, Milano G (1998) Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 4:2039–2045PubMedGoogle Scholar
  8. 8.
    Fowler JF, Lindstrom MJ (1992) Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 23:457–467CrossRefPubMedGoogle Scholar
  9. 9.
    Hitt R, Lopez-Pousa A, Martinez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Marti JL, Lobo F, Pastor P, Valenti V, Belon J, Sanchez MA, Chaib C, Pallares C, Anton A, Cervantes A, Paz-Ares L, Cortes-Funes H (2005) Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636–8645CrossRefPubMedGoogle Scholar
  10. 10.
    Hitt R, Paz-Ares L, Brandariz A, Castellano D, Pena C, Millan JM, Calvo F, Ortiz de Urbina D, Lopez E, Alvarez-Vicent JJ, Cortes-Funes H (2002) Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: long-term results of a phase II trial. Ann Oncol 13:1665–1673CrossRefPubMedGoogle Scholar
  11. 11.
    Innocenti F (ed) (2009) Genomics and pharmacogenomics in anticancer drug development and clinical response. Humana Press, TotowaGoogle Scholar
  12. 12.
    Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L et al (1992) A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10:257–263PubMedGoogle Scholar
  13. 13.
    Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006–2011PubMedGoogle Scholar
  14. 14.
    Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338CrossRefPubMedGoogle Scholar
  15. 15.
    Mercier C, Ciccolini J (2006) Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer 6:288–296CrossRefPubMedGoogle Scholar
  16. 16.
    Mercier C, Yang C, Ciccolini J, Balti M, Evrard A, Blesius A, Dahan L, Richard K, Seitz J, Lacarelle B, Favre R (2006) Determination of uracil/UH2 ratio as a potential surrogate for DPD status in cancer patients presenting with severe toxicities during fluoropyrimidine treatment. J Clin Oncol 24:2020 Meeting AbstractsGoogle Scholar
  17. 17.
    Milano G, Chamorey AL (2002) Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 19:177–189CrossRefPubMedGoogle Scholar
  18. 18.
    Parker WB, Cheng YC (1990) Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48:381–395CrossRefPubMedGoogle Scholar
  19. 19.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMedGoogle Scholar
  20. 20.
    Peters LJ, Withers HR (1997) Applying radiobiological principles to combined modality treatment of head and neck cancer–the time factor. Int J Radiat Oncol Biol Phys 39:831–836CrossRefPubMedGoogle Scholar
  21. 21.
    Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715CrossRefPubMedGoogle Scholar
  22. 22.
    Roos PH, Bolt HM (2005) Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin Drug Metab Toxicol 1:187–202CrossRefPubMedGoogle Scholar
  23. 23.
    Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M, Demard F (1989) 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59:287–290PubMedGoogle Scholar
  24. 24.
    Schneider M, Etienne MC, Milano G, Thyss A, Otto J, Dassonville O, Mobayen H, Saudes L, Guillot T, Demard F (1995) Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol 13:1656–1662PubMedGoogle Scholar
  25. 25.
    Specenier PM, Vermorken JB (2007) Neoadjuvant chemotherapy in head and neck cancer: should it be revisited? Cancer Lett 256:166–177CrossRefPubMedGoogle Scholar
  26. 26.
    Specenier PM, Vermorken JB (2008) Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther 8:375–391CrossRefPubMedGoogle Scholar
  27. 27.
    Sumi S, Kidouchi K, Ohba S, Wada Y (1995) Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography. J Chromatogr B Biomed Appl 672:233–239CrossRefPubMedGoogle Scholar
  28. 28.
    Thyss A, Milano G, Renee N, Vallicioni J, Schneider M, Demard F (1986) Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 16:64–66CrossRefPubMedGoogle Scholar
  29. 29.
    Trump DL, Egorin MJ, Forrest A, Willson JK, Remick S, Tutsch KD (1991) Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol 9:2027–2035PubMedGoogle Scholar
  30. 30.
    van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G > A mutation causing DPD deficiency. Clin Cancer Res 7:1149–1153PubMedGoogle Scholar
  31. 31.
    Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704CrossRefPubMedGoogle Scholar
  32. 32.
    Vokes EE, Mick R, Kies MS, Dolan ME, Malone D, Athanasiadis I, Haraf DJ, Kozloff M, Weichselbaum RR, Ratain MJ (1996) Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 14:1663–1671PubMedGoogle Scholar
  33. 33.
    Walko CM, McLeod HL (2008) Will we ever be ready for blood level-guided therapy? J Clin Oncol 26:2078–2079CrossRefPubMedGoogle Scholar
  34. 34.
    Wihlm J, Leveque D, Velten M, Klein T (1993) Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion. Bull Cancer 80:439–445PubMedGoogle Scholar
  35. 35.
    Worden FP, Moon J, Samlowski W, Clark JI, Dakhil SR, Williamson S, Urba SG, Ensley J, Hussain MH (2006) A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. Cancer 107:319–327CrossRefPubMedGoogle Scholar
  36. 36.
    Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, Gamelin E (2007) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249:271–282CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Chen Guang Yang
    • 1
  • Joseph Ciccolini
    • 2
  • Aurore Blesius
    • 1
  • Laetitia Dahan
    • 3
  • Danielle Bagarry-Liegey
    • 1
  • Caroline Brunet
    • 1
  • Arthur Varoquaux
    • 4
  • Nicolas Frances
    • 5
  • Hafedh Marouani
    • 5
  • Antoine Giovanni
    • 6
  • Rose-Marie Ferri-Dessens
    • 7
  • Mohamed Chefrour
    • 5
  • Roger Favre
    • 1
  • Florence Duffaud
    • 1
  • Jean-François Seitz
    • 3
  • Michel Zanaret
    • 6
  • Bruno Lacarelle
    • 2
  • Cédric Mercier
    • 1
    • 5
    Email author
  1. 1.Medical Oncology UnitLa Timone University HospitalMarseille cedex 05France
  2. 2.Federation de Pharmacologie Medicale et CliniqueLa Timone University HospitalMarseilleFrance
  3. 3.Digestive Oncology UnitLa Timone University HospitalMarseilleFrance
  4. 4.Radiology DepartmentLa Timone University HospitalMarseilleFrance
  5. 5.UMR-MD3, Pharmacokinetics Laboratory, School of PharmacyAix-Marseille UniversityMarseilleFrance
  6. 6.Federation d’OtorhynolaryngologieLa Timone University HospitalMarseilleFrance
  7. 7.Roche OncologieNeuilly sur SeineFrance

Personalised recommendations